Johnson & Johnson announced new two-year results from its Phase 3 ICONIC-LEAD study evaluating the investigational drug ICOTYDE in adults with moderate-to-severe plaque psoriasis. The data, presented at the 2026 European Academy of Dermatology and Venereology Congress, showed consistently high levels of skin clearance and patient-reported symptom improvement at the 112-week mark.
The study results indicated that patients treated with ICOTYDE maintained high efficacy throughout the extended treatment period. The company noted that the data demonstrated sustained skin clearance and improvements in patient-reported outcomes, with no new safety signals observed during the two-year follow-up.
ICOTYDE is an investigational interleukin-23 (IL-23) inhibitor designed for the treatment of moderate-to-severe plaque psoriasis. The ICONIC-LEAD study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of ICOTYDE in this patient population.
